|1.||Christensen, Jennifer L: 1 article (03/2008)|
|2.||Ajami, Alfred M: 1 article (03/2008)|
|3.||Capizzi, Robert L: 1 article (03/2008)|
|4.||Chau, Mydoanh: 1 article (03/2008)|
|5.||Grieshaber, C K: 1 article (07/2007)|
|6.||Alami, N: 1 article (07/2007)|
|7.||Belanger, S: 1 article (07/2007)|
|8.||Juste, S: 1 article (07/2007)|
|9.||Paterson, J: 1 article (07/2007)|
|10.||Leyland-Jones, B: 1 article (07/2007)|
03/01/2008 - "Since clinical trials with amonafide, a unique ATP-independent Topo II inhibitor, in combination with cytarabine, have shown significant efficacy for remission induction in patients with sAML, we compared the cytotoxic effect of amonafide (amonafide l-malate, Xanafide) to the classical Topo II inhibitors (daunorubicin, doxorubicin, idarubicin, etoposide, and mitoxantrone) in K562 leukemia cells and in the MDR subline, K562/DOX. "
|2.||Breast Neoplasms (Breast Cancer)
07/02/2007 - "The current study was conducted to investigate further the anti-proliferative effects of xanafide in human breast cancer cell lines, in vitro and in vivo. "
07/02/2007 - "Comparative analysis of xanafide cytotoxicity in breast cancer cell lines."
07/02/2007 - "Our results show that there is no relationship between sensitivity of these cell lines to xanafide and cellular levels of both isoforms of topoisomerase II and suggest that ER and p53 status and their crosstalk may predict the responsiveness or resistance of breast cancer patients to xanafide."
|1.||Idarubicin (4 Demethoxydaunorubicin)
|3.||Etoposide (VP 16)
|7.||Adenosine Triphosphate (ATP)
|8.||trioctyl phosphine oxide (TOPO)
|10.||malic acid (malate)